A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Oncology Institute, Inc.
TOI
$372M
Mkt Cap
$4.98
-1.78%
Oncology Institute, Inc. (TOI) has a 5-year average return on invested capital (ROIC) of -38.4%. This is below average and may indicate limited pricing power.
Oncology Institute, Inc. (TOI) has a market capitalization of $490M. It is classified as a small-cap stock.
Oncology Institute, Inc. (TOI) does not currently pay a regular dividend.
Oncology Institute, Inc. (TOI) operates in the Services-Offices & Clinics Of Doctors Of Medicine industry, within the Healthcare sector.
Oncology Institute, Inc. (TOI) reported annual revenue of $393 million in its most recent fiscal year, based on SEC EDGAR filings.
Oncology Institute, Inc. (TOI) has a net profit margin of -13.5%. The company is currently unprofitable.
Oncology Institute, Inc. (TOI) generated $-30 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Formed in 2007, the business of what is now The Oncology Institute, Inc. ("TOI", the "Company", "we", or "our) and its affiliated professional corporations was created initially as a collection of community oncology practices in southern California, and has evolved to be a national leader in the pursuit of reducing the ever-rising cost of oncology care, while embracing clinical best practices, state-of-the-art technology, and compassionate treatment of patients. While we continue our original purpose of seeing our patients on a fee-for-service basis for their oncology, hematology, specialty infusion, oral pharmacy needs, as well as enrolling patients in clinical trials, where appropriate, TOI's true mission lies in our differentiated ability to partner with managed care providers and other risk-bearing entities to transfer the risk and patient coordination responsibility of treating cancer in the subset of the population that is experiencing an oncology treatment episode.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 461M | 393M | 324M | 252M | 203M | 188M |
| Net Income | -66M | -53M | -68M | - | -11M | -14M |
| EPS | $-0.64 | $-0.71 | $-0.92 | $-0.21 | $-0.16 | $-0.24 |
| Free Cash Flow | -28M | -30M | -41M | -67M | -36M | -686K |
| ROIC | -89.5% | -54.8% | -47.2% | - | -10.2% | -41.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 25.95 | 1.52 | 0.65 | 0.00 | 0.42 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -41M | -60M | -77M | -82M | -46M | -8.2M |
| Operating Margin | -8.9% | -15.3% | -23.8% | -32.5% | -22.6% | -4.4% |
| ROE | 0.0% | -174.9% | -119.0% | - | -10.2% | -51.0% |
| Shares Outstanding | 98M | 75M | 74M | 74M | 66M | 60M |
| Metric | ||||||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 188M | 203M | 252M | 324M | 393M | 461M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -8.2M | -46M | -82M | -77M | -60M | -41M |
| Op. Margin | -4.4% | -22.6% | -32.5% | -23.8% | -15.3% | -8.9% |
| Net Income | -14M | -11M | N/A | -68M | -53M | -66M |
| Net Margin | -7.6% | -5.2% | N/A | -20.9% | -13.5% | -14.4% |
| Non-Recurring | 0 | 0 | 9.9M | 17M | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -41.3% | -10.2% | N/A | -47.2% | -54.8% | -89.5% |
| ROE | -51.0% | -10.2% | N/A | -119.0% | -174.9% | 0.0% |
| ROA | -21.8% | -5.2% | N/A | -32.4% | -27.8% | -40.5% |
| Cash Flow | ||||||
| Op. Cash Flow | 508K | -33M | -62M | -36M | -27M | -24M |
| Free Cash Flow | -686K | -36M | -67M | -41M | -30M | -28M |
| Owner Earnings | -2.8M | -61M | -94M | -60M | -44M | -41M |
| CapEx | 1.2M | 2.8M | 5.5M | 4.6M | 3.8M | 3.9M |
| Maint. CapEx | 3.2M | 3.3M | 4.4M | 5.9M | 6.3M | 6.3M |
| Growth CapEx | 0 | 0 | 1.1M | 0 | 0 | 0 |
| D&A | 3.2M | 3.3M | 4.4M | 5.9M | 6.3M | 6.3M |
| CapEx/OCF | 235.0% | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 9.0M | 1.0M | 0 | 0 |
| Buyback Yield | N/A | N/A | 8.1% | 0.7% | N/A | 0.0% |
| Stock-Based Comp | 151K | 25M | 28M | 18M | 11M | 11M |
| Debt Repayment | 281K | 7.2M | 3.7M | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | 5.9M | -115M | 6.8M | 4.0M | 43M | 49M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | 28M |
| Long-Term Debt | 6.6M | 0 | 81M | 87M | 93M | 93M |
| Debt/Equity | 0.42 | 0.00 | 0.65 | 1.52 | 25.95 | 0.00 |
| Interest Coverage | -23.6 | -9.3 | -447.8 | -11.4 | -8.0 | -8.0 |
| Equity | 28M | 104M | 123M | 57M | 3.6M | -12M |
| Total Assets | 66M | 203M | 262M | 209M | 173M | 164M |
| Total Liabilities | 38M | 99M | 138M | 152M | 169M | 176M |
| Intangibles | 34M | 45M | 39M | 25M | 22M | 22M |
| Retained Earnings | -52M | -63M | -63M | -146M | -211M | -211M |
| Working Capital | 1.1M | 124M | 101M | 109M | 60M | 60M |
| Current Assets | 30M | 154M | 130M | 143M | 112M | 112M |
| Current Liabilities | 29M | 30M | 30M | 35M | 52M | 52M |
| Per Share Data | ||||||
| EPS | -0.24 | -0.16 | -0.21 | -0.92 | -0.71 | -0.64 |
| Owner EPS | -0.05 | -0.91 | -1.26 | -0.81 | -0.59 | -0.42 |
| Book Value | 0.47 | 1.57 | 1.66 | 0.77 | 0.05 | -0.12 |
| Cash Flow/Share | 0.01 | -0.49 | -0.83 | -0.49 | -0.36 | -0.61 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 59.7M | 66.4M | 74.3M | 73.8M | 74.7M | 98.4M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -7.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 23.0 | 7.0 | 0.9 | 2.7 | 6.6 | N/A |
| Price/Sales | 3.3 | 3.2 | 1.7 | 0.3 | 0.2 | 1.1 |
| FCF Yield | -0.1% | -4.9% | -60.4% | -26.4% | -128.1% | -5.6% |
| Market Cap | 647M | 725M | 111M | 155M | 24M | 490M |
| Avg. Price | 10.27 | 9.90 | 5.77 | 1.15 | 0.85 | 4.98 |
| Year-End Price | 10.85 | 10.91 | 1.50 | 2.10 | 0.32 | 4.98 |
Oncology Institute, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
Oncology Institute, Inc. (TOI) has a debt-to-equity ratio of 25.95. This indicates higher leverage, which may increase financial risk.
Oncology Institute, Inc. (TOI) reported earnings per share (EPS) of $-0.71 in its most recent fiscal year.
Oncology Institute, Inc. (TOI) has a return on equity (ROE) of -174.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for Oncology Institute, Inc. (TOI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Oncology Institute, Inc. (TOI) has a book value per share of $0.05, based on its most recent annual SEC filing.